Antibody-Drug Conjugates and Cellular Metabolic Dynamics

Antibody-Drug Conjugates Basic Concepts and Structures.- Relationship between target and specific action of antibody-drugs conjugates.- The internalization and therapeutic activity of antibody drug conjugate.- The internalization and intracellular trafficking of ADC.- Distribution and metabolism of antibody-drug conjugates.- Application of Antibody fragments in ADCs.- Novel Targeting Carriers in Antibody-drug Conjugates.- Site-specified Conjugating Technology and Application.- Determination of drug-to-antibody ratio of ADCs.- Pharmacokinetic study of antibody-drug conjugates.

Dr. Shuqing Chen received his B.S. and M.S. from Zhejiang Medical University and Ph.D. from Zhejiang University, and had his post-doctor training in Cornell University, USA. He is now the professor and director of lab of precision medicine and biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University. Dr. Chen focus on the design of new biotechnological drugs by employing the technologies of antibody-drug conjugates, fusion protein, bi-specific antibodies etc, and applying the new drug targets from the clue of somatic mutation of the malignant cell. Dr. Chen have published 300 more research papers in international journals. He was chosen as World's Top 2% Scientists 2020 by Elsevier and Stanford University.
Dr. Jinbiao Zhan received his B.S. at College of Pharmacy in 1983, and M.S. at School of Medicine in 1988 from Zhejiang Medical University, and earned his Ph.D. in Zhejiang University Medical School, Hangzhou, China. He worked as visiting fellow inDept of Biological Sciences, University of Warwick, UK from March to October 1993, and then he moved to Seattle and worked as research fellow for three years in Oncology Department of Medical School, University of Washington, USA. Since December 2004, Dr. Zhan has been working as professor at Dept of Biochemistry, and Cancer Institute of Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Dr. Zhan focuses on the research of antibody library, antibody-targeted therapeutics including immunotoxins and antibody-drug conjugates (ADCs). His recent research interests include: screening of human scFv libraries by phage display, engineering of full-length antibodies against PD1/PDL1, mechanism of antibody and ADC endocytosis, development of novel antibody therapeutics against cancers etc. Since 2008, Dr. Zhan has published 70 papers in peer-reviewed journals and obtained 15 patents. He served as a member of editorial boards of several journals, including Antibody Therapeutics,